Adc Therapeutics Sa Stock Return On Asset
| ADCT Stock | USD 1.61 0.09 5.29% |
ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.
Return On Assets is likely to drop to -0.64 in 2025. ADC | Return On Asset |
ADC Therapeutics SA Company Return On Asset Analysis
ADC Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current ADC Therapeutics Return On Asset | -0.21 |
Most of ADC Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ADC Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as Return On Asset. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
ADC Total Assets
Total Assets |
|
Based on the latest financial disclosure, ADC Therapeutics SA has a Return On Asset of -0.2117. This is 97.58% lower than that of the Communications Equipment sector and 99.1% lower than that of the Information Technology industry. The return on asset for all United States stocks is 51.21% higher than that of the company.
ADC Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.ADC Therapeutics is currently under evaluation in return on asset category among its peers.
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 2.1B | 1.6B | 300.1M | 135.6M | 156.0M | 148.2M | |
| Enterprise Value | 1.7B | 1.2B | 91.0M | (18.6M) | (21.4M) | (20.3M) |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Current Valuation | 26.25 M | ||||
| Shares Outstanding | 96.69 M | ||||
| Shares Owned By Insiders | 20.64 % | ||||
| Shares Owned By Institutions | 63.17 % | ||||
| Number Of Shares Shorted | 5.3 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 2.32 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | (59.85 M) | ||||
| EBITDA | (146.76 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.78) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Short Ratio | 11.50 X | ||||
| Earnings Per Share | (2.39) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 8.8 | ||||
| Number Of Employees | 273 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 164.37 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 354.78 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.